Regeneron at neutral by Merrill

Regeneron Pharmaceuticals Inc. was given a neutral rating by Merrill Lynch analyst Hari Sambasivam on news that the company and Sanofi begun a phase 2 trial for VEGF Trap in patients with locally advanced or metastatic lung cancer. Merrill believes 2006 could be an important year for Regeneron as development plans for VEGF Trap are clarified and additional studies begin. Shares of the Tarrytown, N.Y., pharmaceutical company were up 54 cents, or 3.55%, at $15.77 on volume of 471,766 shares versus the three-month running average of 520,744 shares. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.